Derivative exercise or conversion — not an open-market buy.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Aug 27, 2026
Reporting period
Not applicable
Filed with the SEC
Sep 1, 2026
OfficerOption exercise
Context
Classification
option exercise
Code M — exercise or conversion of a derivative security
Planned / mechanical clue
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001737329-26-000016
Filed / recorded
Sep 1, 2026, 2:45 AM UTC
Added to OQRO
Oct 6, 2026, 7:59 PM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
Jazz Pharmaceuticals plc
Issuer CIK
1232524
Ticker
JAZZ
Reporting person
Robert Iannone
Relationship
Officer
Officer title
EVP, Global Head of R&D & CMO
Security
Ordinary Shares
Table
Non-derivative (Table I)
Transaction date
Aug 27, 2026
Transaction code
M
Shares / units
884
Price per share
$113.10
Acquired / disposed
Acquired (A)
Shares owned after
112,107
Ownership form
Direct
Amendment
No
Footnotes from the filing
This transaction was made pursuant to a plan adopted by the reporting person on May 28, 2026 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person.